Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

ProKidney (PROK) Stock Price & Analysis

373 Followers

PROK Stock Chart & Stats

$1.13$0.02(1.80%)
At close: 4:00 PM EST
$1$1.5$2Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.11 - $1.18
52-Week Range
$0.87 - $2.88
Previous Close
$1.11
Volume
N/A
Average Volume (3M)
1.34M
Market Cap
$335.63M
Enterprise Value
$1.31B
Total Cash (Recent Filing)
$181.56M
Total Debt (Recent Filing)
$3.52M
Price to Earnings (P/E)
―
Beta
2.20
Next Earnings
Nov 16, 2026 (Est.)
EPS Estimate
-0.16
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Development Progress

Progress into Phase 3 gives rilparencel a more advanced development profile and provides a defined path toward potential commercialization. Reported kidney-function stabilization in earlier studies supports the therapy’s clinical rationale, although final efficacy and approval remain unproven.

Regulatory And Manufacturing Positioning

RMAT designation can support closer regulatory interaction and potentially streamline development for a serious disease, while in-house manufacturing may improve control over production readiness. Together, these capabilities could strengthen execution as the program advances toward commercialization.

Low Debt Burden

Very low debt limits near-term interest and refinancing pressure, preserving more flexibility for research, clinical development, and manufacturing investment. This is a meaningful balance-sheet advantage for a cash-burning biotech, even though negative equity and funding needs remain substantial constraints.

Bears Say

Substantial Cash Burn

The company is not self-funding and continues to consume cash at a substantial rate, leaving ongoing operations and clinical development dependent on external capital. Persistent outflows reduce financial flexibility and increase the importance of successful financing and future clinical execution.

Minimal Revenue And Large Losses

Very limited revenue relative to operating losses indicates that ProKidney remains pre-commercial and has not established meaningful operating scale. Deeply negative margins and volatile sales limit internal funding capacity, making future financial performance highly dependent on product development success.

Persistent Negative Equity

Multi-year negative equity reflects accumulated deficits or capital-structure complexity and weakens the company’s financial foundation. It can constrain resilience during prolonged development timelines, increase reliance on new financing, and leave less balance-sheet capacity to absorb clinical or commercial setbacks.

ProKidney News

PROK FAQ

What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $0.87 and its highest was $2.88 in the past 12 months.
What is ProKidney’s market cap?
ProKidney’s market cap is $335.63M.
When is ProKidney’s upcoming earnings report date?
ProKidney’s next earnings report is estimated for Nov 16, 2026 (not yet confirmed), which is in 4 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Aug 10, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.01.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -0.16.
How many shares outstanding does ProKidney have?
ProKidney has 208,975,480 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went down -4.734%.
Which hedge fund is a major shareholder of ProKidney?
Hedge funds hold ProKidney shares: the largest hedge-fund position in ProKidney is 71,886,264 shares, and hedge funds increased their holdings by 3.2M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology